O Shaughnessy Asset Management LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 62.1% during the 4th quarter, HoldingsChannel reports. The fund owned 52,650 shares of the biopharmaceutical company’s stock after selling 86,259 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Gilead Sciences were worth $3,293,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Riverview Trust Co purchased a new position in Gilead Sciences in the 4th quarter worth $114,000. Accident Compensation Corp raised its stake in Gilead Sciences by 21.3% in the 4th quarter. Accident Compensation Corp now owns 89,118 shares of the biopharmaceutical company’s stock worth $5,574,000 after acquiring an additional 15,621 shares during the last quarter. TT International raised its stake in Gilead Sciences by 2.5% in the 4th quarter. TT International now owns 90,284 shares of the biopharmaceutical company’s stock worth $5,647,000 after acquiring an additional 2,236 shares during the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in Gilead Sciences by 242.5% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 714,430 shares of the biopharmaceutical company’s stock worth $39,092,000 after acquiring an additional 505,855 shares during the last quarter. Finally, Wellington Shields & Co. LLC purchased a new position in Gilead Sciences in the 4th quarter worth $644,000. 78.23% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Gayle E. Wilson sold 19,068 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total transaction of $1,279,081.44. Following the sale, the director now directly owns 143,567 shares in the company, valued at approximately $9,630,474.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.16% of the stock is owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the business earned $1.78 earnings per share. Gilead Sciences’s revenue was down 2.6% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 6.23 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.89%. Gilead Sciences’s dividend payout ratio (DPR) is 37.07%.
A number of brokerages recently issued reports on GILD. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 23rd. BMO Capital Markets began coverage on Gilead Sciences in a research note on Thursday. They set an “outperform” rating for the company. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 21st. Piper Jaffray Companies set a $75.00 price objective on Gilead Sciences and gave the company a “hold” rating in a research note on Thursday, March 7th. Finally, ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Hold” and an average price target of $82.56.
Gilead Sciences Company Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Google Finance
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.